This article is more than 5 years old. Information may no longer be current.
Invasive pneumococcal disease burden shifts to younger populations in Canada
Click Here to Manage Email Alerts
DENVER — The seven-valent pneumococcal conjugate vaccine led to substantial reductions in invasive pneumococcal disease cases in Canada, but the burden of disease has now shifted to younger populations when compared with the prevaccine era, according to data presented here this week.
Anne E. Wormsbecker, MD, of the Toronto Invasive Bacterial Diseases Network, Hospital for Sick Children, in Toronto, Canada, reported on ongoing surveillance at the Pediatric Academic Societies’ Annual Meeting 2011.
She said that prior to the introduction of the seven-valent pneumococcal vaccine (PCV7, Prevnar, Wyeth), the invasive pneumococcal disease rate in children aged younger than 5 years was 35 per 100,000. In 2006, the rate dropped to 9.6 per 100,000. The rate rebounded somewhat in 2009 to 23 per 100,000, which Wormsbecker attributed to replacement serotypes. She said some of those dominating replacement serotypes can be found in the 13-valent pneumococcal vaccine (PCV13, Prevnar13, Wyeth) vaccine, including type 19A.
“A shift in IPD to children aged 2 to 5 years old suggests that catch-up PCV13 doses could optimize program impact,” she said.
She noted that in 2009, five of 71 isolates were resistant to amoxicillin compared with none in the prevaccine era.
Wormsbecker told the audience that both meningitis and bacteremia rates dropped over time, but pneumonia incidence actually increased (all P<.05).
Unfortunately, the burden of invasive pneumococcal disease shifted from 43% in children aged younger than 5 in the prevaccine era to 61% in 2009.
Disclosures: Dr. Wormsbecker received the CIHR Rx&D Fellowship Award from Wyeth Pharmaceuticals.
For more information:
 |
Follow the PediatricSuperSite.com on Twitter. |